| Getein 1100 |
| Test Item |
Disease |
Measuring Range |
Sample |
Cut-off Value |
Reaction Time |
Qualification |
| cTnI |
Myocardial Infarction |
0.1 – 50.0 ng/ml |
S/P/W.B. |
0.1 ng/ml |
10 min |
CE CFDA |
| NT-proBNP | Heart Failure | 100 – 35000 pg/ml | S/P/W.B. | 300 pg/ml | 10 min | CE CFDA |
| Hs-CRP + CRP | Cardiovascular inflammatory disease; Inflammatory disorders | 0.5 – 200.0 mg/L | S/P/W.B./ Fingertip blood | 3 mg/L 10 mg/L | 3 min | CE CFDA |
| CKMB /cTnI /Myo | Myocardial Injury | 2.5 – 80.0 ng/ml 0.1 – 50.0 ng/ml 30.0 – 600.0 ng/ml | S/P/W.B. | 5 ng/ml 0.1 ng/ml
70 ng/ml | 10 min | CE CFDA |
| D-Dimer | Venous Thromboembolism, Pulmonary embolism | 0.1 – 10.0 mg/L | P/W.B. | 0.5 mg/L | 10 min | CE CFDA |
| PCT | Sepsis; Septic Shock | 0.1 – 50 ng/ml | S/P/W.B. | 0.1 ng/ml | 15 min | CE CFDA |
| Cystatin C | Early diagnosis of kidney disease; Detection of kidney damage for surgery patients | 0.5 – 10 mg/L | S/P/W.B. | 0.51 – 1.09 mg/L | 3 min | CE CFDA |
| mALB | Early diagnosis and evaluation of diabetic nephropathy | 10 – 200 mg/L | Urine | 20 mg/L | 3 min | CE CFDA |
| NGAL | The best indicator of early renal injury | 50 – 5000 ng/ml | S/Urine | Serum: 200 ng/ml, Urine: 100 ng/ml | 10 min | CE CFDA |
| B2 –MG | Kidney damage for diabetic and hypertensive patients | 0.5 – 20.0 mg/L | S/P/W.B. | 0.8 – 3.0 mg/L | 3 min | CE CFDA |
| CK-MB/cTnI | Myocardial injury | 2.5 – 80.0 ng/ml 0.1 – 50.0 ng/ml | S/P/W.B. | 5 ng/ml
0.1 ng/ml | 10 min | CE |
| H-FABP | Acute Myocardial Infarction; Heart failure | 1.0 -120.0 ng/ml | S/P/W.B. | 3.94 ng/ml | 3 min | CE CFDA |
| HbA1c | Diabetes Mellitus | 2% - 14% | W.B. | 3.8% – 5.8% | 5 min | CE CFDA NGSP |
| CK-MB | Myocardial Injury | 2.5 – 80.0 ng/ml | S/P/W.B. | 5 ng/ml | 10 min | CE |
| TSH | Thyroid disease | 0.1 – 50.0 µIU/ml | S/P | 0.27 – 4.2 µIU/ml | 15 min | CE |
